Evidence map›Paper›PMID 32503978›Full record

ArticleNature communications2020

MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.

Srividya Swaminathan, Aida S Hansen, Line D Heftdal, Renumathy Dhanasekaran, Anja Deutzmann, Wadie D M Fernandez, Daniel F Liefwalker, Crista Horton, Adriane Mosley, Mariola Liebersbach and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Srividya Swaminathan *Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Aida S Hansen *Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6547-8393
Line D HeftdalDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6946-7341
Renumathy DhanasekaranDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Anja DeutzmannDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Wadie D M FernandezDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Daniel F LiefwalkerDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9516-9690
Crista HortonDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Adriane MosleyDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Mariola LiebersbachDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Holden T MaeckerThe Human Immune Monitoring Center (HIMC), Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Dean W FelsherDivision of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA. dfelsher@stanford.edu.ORCID http://orcid.org/0000-0003-2496-523X
Stanford University · USCity of Hope · USStanford Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
Targeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9M
TUMOR BIOLOGYT32CA009151 · NCI · STANFORD UNIVERSITY · PI CLEARY, MICHAEL L · 1985 to 2014
$5.5M
Modeling and Predicting Therapeutic Resistance of CancerU01CA188383 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, GAMBHIR, SANJIV S · 2014 to 2018
$3.2M
Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)K08CA222676 · NCI · STANFORD UNIVERSITY · PI DHANASEKARAN, RENUMATHY · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA222676NCI NIH HHS R35 CA253180NCI NIH HHS T32 CA009151NCI NIH HHS U01 CA188383
6 · The paper itself

Abstract

The MYC oncogene drives T- and B- lymphoid malignancies, including Burkitt's lymphoma (BL) and Acute Lymphoblastic Leukemia (ALL). Here, we demonstrate a systemic reduction in natural killer (NK) cell numbers in SRα-tTA/Tet-O-MYC

Indexed as

Adoptive TransferAnimalsBurkitt LymphomaCell Line, TumorDisease Models, AnimalGene Expression Regulation, NeoplasticHumansImmunologic SurveillanceInterferon Type IKiller Cells, NaturalLymphoma, T-CellMaleMicePrimary Cell CultureProto-Oncogene Proteins c-mycSignal TransductionInterferon Type IMYC protein, humanMyc protein, mouseProto-Oncogene Proteins c-mycSTAT1 Transcription FactorSTAT2 Transcription Factor

Identifiers

PMID32503978
PMCPMC7275060
OpenAlexW3034061361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.